Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC1 | Q13547 | 4/20 | 0.56 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.47 |
| ▸ | HDAC3 | O15379 | 2/20 | 0.46 |
| ▸ | HDAC2 | Q92769 | 2/20 | 0.46 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.46 |
| ▸ | RAB9A | P51151 | 3/20 | 0.41 |
| ▸ | NPC1 | O15118 | 2/20 | 0.41 |
| ▸ | NCOR2 | Q9Y618 | 1/20 | 0.41 |
| ▸ | MEN1 | O00255 | 3/20 | 0.41 |
| ▸ | CA12 | O43570 | 1/20 | 0.41 |
| ▸ | CA1 | P00915 | 1/20 | 0.41 |
| ▸ | CA2 | P00918 | 1/20 | 0.41 |
| ▸ | CA9 | Q16790 | 1/20 | 0.41 |
| ▸ | NLRP3 | Q96P20 | 1/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
| ▸ | CASP3 | P42574 | 1/20 | 0.41 |
| ▸ | SENP8 | Q96LD8 | 1/20 | 0.41 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.41 |
| ▸ | SENP7 | Q9BQF6 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2095077 | 0.86 | KMT2A (0.62) | KMT2AALDH1A1RAB9ANPC1MEN1 | |
| SCHEMBL601500 | 0.83 | HDAC1 (0.72) | HDAC1KMT2AALDH1A1HDAC3HDAC2 | |
| SCHEMBL30954547 | 0.83 | HDAC1 (0.72) | HDAC1KMT2AALDH1A1HDAC3HDAC2 | |
| SCHEMBL20050944 | 0.80 | HDAC1 (0.52) | HDAC1KMT2AALDH1A1HDAC3HDAC2 | |
| SCHEMBL16886016 | 0.80 | HDAC1 (0.72) | HDAC1KMT2AALDH1A1HDAC3HDAC2 | |
| SCHEMBL29549372 | 0.79 | HDAC1 (0.51) | HDAC1KMT2AALDH1A1HDAC3HDAC2 | |
| SCHEMBL22807460 | 0.79 | HDAC1 (0.51) | HDAC1KMT2AALDH1A1HDAC3HDAC2 | |
| SCHEMBL16176784 | 0.78 | KMT2A (0.50) | KMT2AALDH1A1RAB9ANPC1MEN1 | |
| SCHEMBL7254610 | 0.78 | TSHR (0.43) | HDAC1KMT2AHDAC3HDAC2MAPK1 | |
| SCHEMBL13363243 | 0.78 | HDAC1 (0.53) | HDAC1KMT2AALDH1A1HDAC3HDAC2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023067355-A1 | HETEROCYCLIC COMPOUNDS FOR USE IN THE TREATMENT OF CANCER | ARTIOS PHARMA LIMITED (GB) | 2023-04-27 | — | — | WO | disclosed |
| WO-2023067353-A1 | HETEROCYCLIC COMPOUNDS FOR USE IN THE TREATMENT OF CANCER | ARTIOS PHARMA LIMITED (GB) | 2023-04-27 | — | — | WO | disclosed |
| US-11377423-B2 | Inhibitors of histone deacetylase | THE BROAD INSTITUTE, INC. (US) | 2022-07-05 | — | — | US | disclosed |
| EP-2877444-B1 | INHIBITORS OF HISTONE DEACETYLASE | BROAD INST INC (US) | 2020-09-02 | — | — | EP | disclosed |
| US-20180072671-A1 | INHIBITORS OF HISTONE DEACETYLASE | THE BROAD INSTITUTE, INC. (US) | 2018-03-15 | — | — | US | disclosed |
| US-9790184-B2 | Inhibitors of histone deacetylase | THE BROAD INSTITUTE, INC. (US) | 2017-10-17 | — | — | US | disclosed |
| US-20150191427-A1 | INHIBITORS OF HISTONE DEACETYLASE | THE GENERAL HOSPITAL CORPORATION D/B/A MASSACHUSETTS GENERAL HOSPITAL (US) | 2015-07-09 | — | — | US | disclosed |
| EP-2877444-A1 | INHIBITORS OF HISTONE DEACETYLASE | The Broad Institute, Inc. (US) | 2015-06-03 | — | — | EP | disclosed |
| WO-2014018979-A1 | INHIBITORS OF HISTONE DEACETYLASE | THE BROAD INSTITUTE, INC. (US) | 2014-01-30 | — | — | WO | disclosed |
| US-20080280933-A1 | BENZIMIDAZOLYL COMPOUNDS | EFREMOV IVAN | 2008-11-13 | — | — | US | disclosed |
| WO-2008012623-A1 | BENZIMIDAZOLYL COMPOUNDS AS POTENTIATORS OF MGLUR2 SUBTYPE OF GLUTAMATE RECEPTOR | PFIZER PRODUCTS INC. (US) | 2008-01-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080280933-A1 | BENZIMIDAZOLYL COMPOUNDS | PAICS, TMBIM6, ABCG2 | HDAC1 608/4885KMT2A 3751/4885ALDH1A1 260/4885 |
| US-20180072671-A1 | INHIBITORS OF HISTONE DEACETYLASE | HDAC3, HDAC1, HDAC11 | HDAC1 2/4885KMT2A 146/4885ALDH1A1 1955/4885 |
| US-20150191427-A1 | INHIBITORS OF HISTONE DEACETYLASE | HDAC3, HDAC1, HDAC5 | HDAC1 2/4885KMT2A 174/4885ALDH1A1 2035/4885 |
| US-11377423-B2 | Inhibitors of histone deacetylase | HDAC3, HDAC1, HDAC11 | HDAC1 2/4885KMT2A 144/4885ALDH1A1 2183/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.